AKTX - CIK 0001541157
The table below shows Akari Therapeutics Plc's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $0.00 | $2.60M | $3.85M | $13.25M | $9.36M | $14.06M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.46M |
| $2.95M |
| $4.34M |
| $13.81M |
| $11.63M |
| $14.58M |
| Property, plant & equipment | - | - | - | $0.00 | $0.00 | $0.00 |
| Goodwill | $8.43M | $8.43M | - | - | - | - |
| Total assets | $47.89M | $50.56M | $4.36M | $13.83M | $11.65M | $14.60M |
| Accounts payable | $8.77M | $12.41M | $1.67M | $946.66K | $1.79M | $3.38M |
| Total current liabilities | $12.35M | $19.91M | - | - | - | - |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $19.56M | $28.33M | $4.58M | $12.04M | $6.09M | $5.22M |
| Retained earnings | -$264.55M | -$247.25M | -$227.46M | -$217.45M | -$199.71M | -$182.28M |
| Total equity | $28.33M | $22.23M | -$229.00K | $1.79M | $5.55M | $9.38M |